Circulating biomarkers for early detection and clinical management of colorectal cancer.
Cell-free DNA
Circulating tumor cells (CTC)
Liquid biopsy
MicroRNA
Prognosis
Screening
Journal
Molecular aspects of medicine
ISSN: 1872-9452
Titre abrégé: Mol Aspects Med
Pays: England
ID NLM: 7603128
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
16
01
2019
revised:
07
06
2019
accepted:
08
06
2019
pubmed:
13
6
2019
medline:
4
6
2020
entrez:
13
6
2019
Statut:
ppublish
Résumé
New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations.
Identifiants
pubmed: 31189073
pii: S0098-2997(19)30009-3
doi: 10.1016/j.mam.2019.06.002
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating MicroRNA
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-122Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.